丹麦新生儿侵袭性B族链球菌疾病后癫痫的长期风险
丹麦基于人群的队列研究纳入1997至2017年出生、0至89天诊断为侵袭性B族链球菌病(iGBS)的1432名婴儿(败血症1264例、脑膜炎168例),并按10:1随机匹配一般人群对照14211名。随访至2018年底,iGBS组0至22岁癫痫累积风险为3.6%(95%CI 2.6%-5.0%),对照组2.3%(95%CI 1.9%-2.7%);脑膜炎组15.1%(95%CI 8.9%-22.8%),败血症组2.2%(95%CI 1.4%-3.4%)。调整后癫痫风险比为2.04(95%CI 1.46-2.85)。男性、早产及母亲低社会经济地位与儿童后期癫痫风险升高相关,并修饰该关联。
要点
- 新生儿iGBS病后0至22岁癫痫累积风险3.6%(95%CI 2.6%-5.0%),高于对照组的2.3%(95%CI 1.9%-2.7%)。
- iGBS脑膜炎后癫痫累积风险15.1%(95%CI 8.9%-22.8%),明显高于iGBS败血症的2.2%(95%CI 1.4%-3.4%)。
- 调整后iGBS病与癫痫风险升高相关,HR 2.04(95%CI 1.46-2.85)。
- 男性、早产或母亲低社会经济地位与儿童后期癫痫风险升高相关,并在加法尺度上修饰iGBS与癫痫的关联。
适用人群与场景
- 丹麦1997年至2017年出生、0至89天诊断为侵袭性B族链球菌病(败血症或脑膜炎)的婴儿,随访至2018年底。
- 对照为按性别、出生年月和胎龄10:1随机匹配的一般人群婴儿。
- 社会经济地位由母亲收入和教育定义。
诊断标准与关键阈值
- 侵袭性B族链球菌病:出生后89天内医院诊断为败血症或脑膜炎。
- 癫痫:根据丹麦医学登记数据中的国际疾病分类第十版编码和/或抗癫痫药物处方编码定义。
研究设计与关键结果
- 基于人群的队列研究,纳入1432名iGBS婴儿(792名[55.3%]男孩;1126名[78.6%]胎龄≥37周),其中败血症1264例、脑膜炎168例;对照队列14211名(7869名[55.4%]男孩;11260名[79.2%]胎龄≥37周)。
- 0至22岁癫痫总体累积风险:iGBS组3.6%(95%CI 2.6%-5.0%),对照组2.3%(95%CI 1.9%-2.7%)。
- iGBS脑膜炎后癫痫累积风险15.1%(95%CI 8.9%-22.8%),iGBS败血症后2.2%(95%CI 1.4%-3.4%)。
- iGBS病与癫痫的调整风险比为2.04(95%CI 1.46-2.85)。
- 男性、早产或母亲低社会经济地位与儿童后期癫痫风险升高相关,并在加法尺度上修饰iGBS与癫痫的关联。
证据类型、等级与局限
- 证据类型:基于丹麦全国登记数据的基于人群的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,新生儿iGBS病与儿童后期癫痫发生率升高相关,尤其是脑膜炎后;早产、性别和母亲低社会经济地位修饰该关联。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The risk of epilepsy after neonatal invasive Group B Streptococcus (iGBS) disease, particularly iGBS sepsis, is poorly understood.
OBJECTIVE: To examine the association between neonatal iGBS (sepsis or meningitis) and long-term risk of epilepsy, stratified by sex, prematurity, and maternal socioeconomic position (SEP).
DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study was conducted in Denmark with an inclusion period from 1997 through 2017 and follow-up until the end of 2018. A general population comparison cohort was randomly sampled and matched up to 10:1 to the exposed cohort. Linkage between Danish national registers were applied for data collection. Participants were infants aged 0 to 89 days. The general population comparison cohort was matched by sex, the child's year and month of birth, and gestational age. SEP was defined by maternal income and education.
EXPOSURE: Hospital-diagnosed iGBS (sepsis or meningitis) during the first 89 days after birth.
OUTCOMES AND MEASURES: Epilepsy was defined by International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes and/or prescription codes for antiepileptic drugs using Danish medical registry data. Cumulative risk (CR) of epilepsy was calculated by treating death as a competing event. Cox proportional hazards regression was used to estimate hazard ratios with 95% CIs. Effect modification by sex, prematurity, and maternal SEP was assessed on an additive scale.
RESULTS: A total of 1432 children (792 [55.3%] boys; 1126 [78.6%] with gestational age ≥37 weeks) were identified with iGBS disease: 1264 with sepsis and 168 with meningitis. In the comparison cohort, there were 14 211 children (7869 [55.4%] boys; 11 260 [79.2%] with gestational age ≥37 weeks). The overall (0 to 22 years) CR of epilepsy was 3.6% (95% CI, 2.6%-5.0%) in children with iGBS disease and 2.3% (95% CI, 1.9%-2.7%) in the comparison cohort. The overall CR of epilepsy for iGBS meningitis was 15.1% (95% CI, 8.9%-22.8%) and 2.2% (95% CI, 1.4%-3.4%) for iGBS sepsis. The adjusted hazard ratio for epilepsy in children with iGBS disease was 2.04 (95% CI, 1.46-2.85). Being a boy, born premature, or born to a mother belonging to a low SEP group was associated with an increased risk of epilepsy in later childhood.
CONCLUSION: In this population-based cohort study of 1432 neonates, iGBS disease was associated with a higher incidence of epilepsy in later childhood, notably after meningitis. Premature birth, sex, and low maternal SEP modified the association.
参考来源
- Lykke MR, Sørensen HT, Lawn JE, et al. Long-term Risk of Epilepsy Following Invasive Group B Streptococcus Disease in Neonates in Denmark. JAMA Netw Open. 2023. PMID: 37083662. doi:10.1001/jamanetworkopen.2023.9507
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。